MGMT and glioblastoma: The GLARIUS randomized phase II trial explored BEV + irinotecan as an alternative to TMZ for patients with newly diagnosed GBM, unmethylated O6-methylguanine-DNA methyltransferase (MGMT) status, and for whom the TMZ regimen is expected to be less beneficial [26].